Old drug may help aging hearts
Press Democrat, The (Santa Rosa, CA)
June 11--Aging mice with ailing hearts have gotten a boost from a drug discovered on Easter Island in the 1970s, offering substantive new evidence that the drug could help humans live longer and healthier lives, a Buck Institute scientist said.
After just three months of treatment with rapamycin, the laboratory mice -- at an age comparable to people in their 70s -- had revitalized hearts and also spent more time on running wheels.
"It was a fairly dramatic result," said Simon Melov, a faculty member at the Buck Institute for Research on Aging, located in Novato.
Ultrasound imaging showed the mice's hearts had become more efficient at pumping blood, and genetic analysis identified the mechanisms responsible for the improvement, he said.
The study, reported this week in the online journal Aging Cell, offered "the first evidence that age-related heart dysfunction can be improved even in late life via appropriate drug treatment," Melov said.
Scientists are in a race against the prospect that treating 78 million baby boomers for an array of age-related diseases could double the nation's annual health care costs to $4 trillion, with half of it spent on care for the elderly.
Heart disease, the leading cause of death in the United States, claims about 600,000 lives a year and costs about $109 billion each year.
Melov, a Petaluma resident, said there is "a real demand" for medications to treat an aging population, an urgency that has prompted increased focus on drugs like rapamycin that are already deemed safe for human consumption.
Several studies have found that rapamycin extends the lifespan in animals, but Buck's is the first to demonstrate improved function, he said.
Researchers at the Mayo Clinic are recruiting elderly people with heart disease as participants in a clinical trial using rapamycin, a study unrelated to the Buck Institute's work.
Rapamycin is approved for use as an antifungal agent, treatment for some cancers and to control patient reaction to transplanted kidneys.
Extending human lifespan -- currently at 78.7 years -- is of little use unless people are relatively healthy, leading to the term "healthspan," Melov said.
"You don't want extended decrepitude," he said.
The mice given rapamycin in his study "showed remarkable improvement" in heart function, while the untreated mice continued to decline.
His next step is to assess the impacts on mice given a year-long treatment with rapamycin, looking for benefits to other tissues, such as bones.
In the three-month study, the mice with demonstrably stronger hearts also spent more time on running wheels, a finding that invites speculation, Melov said.
"Maybe it's because they felt better," he said.
(c)2013 The Press Democrat (Santa Rosa, Calif.)
Visit The Press Democrat (Santa Rosa, Calif.) at www.pressdemocrat.com
Distributed by MCT Information Services